CTOs on the Move

Elcelyx Therapeutics

www.elcelyx.com

 
lcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx`s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.elcelyx.com
  • 11995 El Camino Real Suite 305
    San Diego, CA USA 92130-2567
  • Phone: 858.876.1814

Executives

Name Title Contact Details

Funding

Elcelyx Therapeutics raised $40M on 10/01/2015

Similar Companies

Proper

Proper is the modern approach to better sleep - evidence-based, personalized, and holistic, offering premium PhD-designed natural sleep supplements & expert sleep coaching.

First Care Ambulance

First Care Ambulance is a Aurora, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Huntington Hospital

Huntington Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Huntington Hospital is based in Huntington, NY. You can find more information on Huntington Hospital at www.hunthosp.org

T Z Medical Inc

T Z Medical Inc is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kymera Therapeutics

Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.